Skip to content
Head to head

Agios Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: AGIO · VRTX

Updated 5 minutes ago

1-year performance, rebased to 100

AGIO -38.8%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
AGIOVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price27.60515.02
Change today-4.03%-1.08%
1-year return+12.3%+22.0%
Market cap$1.65B$130.58B
52-week range24.16 – 44.09412.27 – 568.67
Valuation
P/E (TTM)-4.3733.14
P/E percentile, own 5-yr range48th99th
P/B1.696.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-7.1215.32
Net profit (TTM)$-425.84M$3.88B
Revenue (TTM)$140.84M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+330.0%+11.8%
Gross margin93.8%85.5%
Operating margin-297.7%33.1%
Net margin-264.8%30.7%
Free cash flow (TTM)$-360.97M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership117.2%96.8%
Insider activity (12mo)37 buy / 13 sell28 buy / 22 sell
Short interest (% of float)10.9%1.9%
Analyst consensus67% buy / 33% hold (6)95% buy / 5% hold (21)
Analyst price target$46 (+66%)$624 (+21%)
StockVane view
StockVane Quant RatingD (69)C (68)
Company
Employees5406,400
Founded20071989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.